The National Lung Cancer Partnership (NLCP) has released a confident, new vision that aims to reduce lung cancer statistics in the U.S., which presently reports 220,000 diagnoses each year, accounting for 27% of cancer mortalities — outnumbering those caused by breast, prostate, and colon cancers combined. Under the leadership of Joan Schiller, MD, president of the National Lung Cancer Partnership and chief of hematology/oncology at the University of Texas Southwestern Medical Center, the NLCP sees itself doubling lung cancer survival rate by the year 2022.
Dr. Schiller shares her perspectives in an article from the International Business Times:
“At the heart of this new vision is a promise that everyone diagnosed with lung cancer will have a greater chance of survival than ever before. We’re committed to the dedication, collaboration and inspiration it will take to achieve this ambitious vision because we are committed to every single person across the country whose life has been touched by lung cancer.”
The Partnership’s new, bold vision contains four quantifiable goals. First is to fund research with the greatest potential to save lives. Second, to help all patients fully understand their treatment options. Third, to ensure molecular tumor testing is the standard of care, and lastly, to double the number of lung cancer patients participating in clinical trials.
Visit www.nationallungcancerpartnership.org/vision to view the Partnership’s full vision.